As a basic scientist, James Allison, PhD, didn’t always meet the patients who benefitted from treatments he discovered, but he did meet 1 woman who participated in one of the early trials of ipilimumab.
As a basic scientist, James Allison, PhD, didn’t always meet the patients who benefitted from treatments he discovered, but he did meet 1 woman who participated in one of the early trials of ipilimumab.
What is it like meeting patients who have been treated with ipilimumab?
Well, as a scientist, all of my early work was with mice. And, of course, they don’t thank you for curing them. Of course, maybe, they shouldn’t because we gave them the cancer in the first place. For several years after the clinical trial started with ipilimumab, I was kind of distant from it; I just kind of saw it as numbers. Because my own family has had a lot of cancer, and I knew what it meant.
It wasn’t until I met the first patient that it really struck me. What had happened was this was a woman who was diagnosed with metastatic melanoma when she was 22, had just finished college, she was engaged, she was about to get married, and diagnosed with metastatic melanoma, so she had lung mats, cutaneous mats, etc, and was really bad off. She’d failed everything and went into one of the early trials of ipilimumab, and I met her when she was first declared tumor free. Doctors said, “the guy who invented this drug is here at Sloan Kettering, do you want to meet him?” And she said, “of course” and I went over, and it was the most emotional thing I’ve experienced, I’ve had, I think.
But then a few years later, 3 or 4 years later, she sent me a photo of her first baby, and a few years after that a photo of her second. She’s 14 years out now. She has this dynamic family and is doing fine and that to me, sort of, illustrates not only is the person saved, but her lineage is saved. For a basic scientist that’s about as good as it gets.
Inside the Center's MDD Value Model and Its Use of Dynamic Pricing
May 13th 2025Larragem Raines, MS, of the Center for Innovation & Value Research, discusses the organization's major depressive disorder (MDD) open-source value model, dynamic pricing, and the future role of artificial intelligence in care.
Listen
What's at Stake as Oral Arguments Are Presented in the Braidwood Case? Q&A With Richard Hughes IV
April 21st 2025Richard Hughes IV, JD, MPH, spoke about the upcoming oral arguments to be presented to the Supreme Court regarding the Braidwood case, which would determine how preventive services are guaranteed insurance coverage.
Read More
Orca-T showed lower rates of graft-vs-host disease or infection compared with allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome (MDS) or acute leukemias in the Precision-T trial, Caspian Oliai, MD, MS, UCLA Bone Marrow Transplantation Stem Cell Processing Center, said.
Read More